SCM
MAZE

Sterling Capital Management’s Maze Therapeutics MAZE Stock Holding History

Sterling Capital Management’s Portfolio MAZE Stock Details MAZE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$6.62K Sell
222
-607
-73% -$15.9K ﹤0.01% 2461
2026
Q1 		$24.7K Sell
829
-332
-29% -$14.7K ﹤0.01% 1926
2025
Q4 		$48.1K Sell
1,161
-99
-8% -$3.4K ﹤0.01% 1818
2025
Q3 		$32.7K Buy
1,260
+1,036
+463% +$17.5K ﹤0.01% 1918
2025
Q2 		$2.75K Buy
224
+150
+203% +$1.56K ﹤0.01% 2820
2025
Q1 		$815 Buy
+74
New +$891 ﹤0.01% 2878

Other funds holding MAZE

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
ACM
AH Capital Management Menlo Park, California $14.2B AUM 20.01% 1-Year Est. Return

Sterling Capital Management's MAZE Position: Q2 2026 in Review

Sterling Capital Management reduced its Maze Therapeutics (MAZE) stake by 73% in Q2 2026, selling an estimated $15.9K and leaving 222 shares worth $6.62K. The position accounts for ﹤0.01% of the portfolio, ranked #2461.

Sterling Capital Management first reported a position in MAZE in Q1 2025 and has held it in 6 quarters since. The position peaked at $48.1K in Q4 2025. 162 funds tracked by Wall St. Rank hold MAZE as of Q2 2026.

  • Sterling Capital Management held 222 shares of Maze Therapeutics worth $6.62K as of Q2 2026.
  • Sterling Capital Management sold 607 Maze Therapeutics shares in Q2 2026, an estimated $15.9K.
  • Maze Therapeutics made up ﹤0.01% of Sterling Capital Management's portfolio in Q2 2026, its #2461 holding.
  • Sterling Capital Management first reported a position in Maze Therapeutics in Q1 2025 and has held it in 6 quarters since.
  • Sterling Capital Management's Maze Therapeutics position peaked at $48.1K in Q4 2025.
  • 162 funds tracked by Wall St. Rank held Maze Therapeutics as of Q2 2026.

Based on Sterling Capital Management's 13F filing for Q2 2026, filed 28 Jul 2026.